- Home
- SWBI vs ALLO Comparison
SWBI vs ALLO Comparison
Compare SWBI & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SWBI | ALLO |
|---|---|---|
| Founded | 1852 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 637.4M | 597.7M |
| IPO Year | 2000 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SWBI | ALLO |
|---|---|---|
| Price | $13.97 | $1.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 15 |
| Target Price | ★ $14.00 | $8.35 |
| AVG Volume (30 Days) | 576.1K | ★ 4.8M |
| Earning Date | 06-17-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.37% | N/A |
| EPS Growth | ★ 36.67 | 34.09 |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $523,845,000.00 | N/A |
| Revenue This Year | $7.61 | N/A |
| Revenue Next Year | $3.72 | $142,416.42 |
| P/E Ratio | $233.67 | ★ N/A |
| Revenue Growth | ★ 10.36 | N/A |
| 52 Week Low | $8.14 | $1.04 |
| 52 Week High | $17.56 | $4.46 |
Technical Indicators
Market Signals| Indicator | SWBI | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 58.63 | N/A |
| Support Level | $13.83 | N/A |
| Resistance Level | $14.32 | N/A |
| Average True Range (ATR) | 0.52 | 0.00 |
| MACD | 0.17 | 0.00 |
| Stochastic Oscillator | 93.58 | 0.00 |
Price Performance
Historical ComparisonAbout SWBI Smith & Wesson Brands Inc.
Smith & Wesson Brands Inc is a U.S.-based company engaged in manufacturing and selling firearms. It operates under one reportable segment: Firearms, which includes firearms distribution and manufacturing services. The company manufactures handguns, long guns, sporting rifles, shooting gear, and suppressor products. The company sells its products under the Smith and Wesson and Gemtech brands, which are used for defense, law enforcement, hunting, and sporting purposes. Geographically, it sells products globally, with maximum income being generated by the U.S. market from its handgun products.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).